Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Cell Therapeutics, Inc. (CTI) Reports Reduction in Operating Expenses and Net Losses for Second Quarter and First Half 2011 Compared to 2010, and Advances In Bringing Pixantro…

July 28, 2011 By Bio-Medicine.Org

SEATTLE, July 28, 2011 /PRNewswire/ — Cell Therapeutics, Inc.
(“CTI” or the “Company”) (NASDAQ and MTA: CTIC) today reported
advancements in its efforts to develop its late stage oncology
pipeline to market coupled with improved financial results for the
second quarter ended June 30, 2011.

“In the second quarter, we seized on the momentum and the
feedback provided by the FDA’s Office of New Drugs (“OND”) in
allowing us to resubmit the pixantrone New Drug Application (“NDA”)
based on the PIX 301 data without requiring the Company to conduct
additional clinical trials in advance of potential accelerated
approval. Our type A meeting with the FDA’s Division of Oncology
Drug Products (“DODP”) provided guidance on items in the Complete
Response Letter and we are on track to provide this information, as
well as the information OND requested, in the fourth quarter of
2011,” said James A. Bianco, M.D., Chief Executive Officer of the
Company. “With a six month review process after resubmission,
approval of pixantrone in the United States may occur as early as
April 2012.  Similarly, our meeting in April with
representatives of the European Medicines Agency (“EMA”) and our
Marketing Authorization Application (“MAA”) co-rapporteurs provided
guidance for responding to the Day 120 letter that could allow a
recommendation for approval before year end.”

“In addition to these significant developments in advancing
pixantrone to market, encouraging phase II tosedostat results,
which were reported at ASCO, suggest a target population for a
phase II/III registration-directed trial, which we expect to get
underway in the first half of 2012 following an FDA meeting that we
will request later this year. With OPAXIO advancing to its interim
survival analysis in the phase III front-line maintenance ovarian
cancer study and brostallicin generating excitement in the Mayo
Clinic’s North Central Cancer Treatment Groups’ triple negative
breast cancer study, 2012 can be a p

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech